185 related articles for article (PubMed ID: 37557966)
21. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.
Heinze K; Cairns ES; Thornton S; Harris B; Milne K; Grube M; Meyer C; Karnezis AN; Fereday S; Garsed DW; Leung SCY; Chiu DS; Moubarak M; Harter P; Heitz F; McAlpine JN; DeFazio A; Bowtell DDL; Goode EL; Pike M; Ramus SJ; Pearce CL; Staebler A; Köbel M; Kommoss S; Talhouk A; Nelson BH; Anglesio MS
Clin Cancer Res; 2023 Sep; 29(17):3471-3483. PubMed ID: 37339172
[TBL] [Abstract][Full Text] [Related]
23. Estrogen Receptor-β Expression of Ovarian Tumors and Its Association with Ovarian Cancer Risk Factors.
Shafrir AL; Babic A; Gates Kuliszewski M; Rice MS; Townsend MK; Hecht JL; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2020 Nov; 29(11):2211-2219. PubMed ID: 32856599
[TBL] [Abstract][Full Text] [Related]
24. [Serous and non-serous ovarian carcinoma: histological tumor type as related to the grade of differentiation and disease prognosis].
Ferreira PA; Sallum LF; Sarian LO; Andrade LA; Derchain S
Rev Bras Ginecol Obstet; 2012 May; 34(5):196-202. PubMed ID: 22584853
[TBL] [Abstract][Full Text] [Related]
25. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.
Truxova I; Kasikova L; Hensler M; Skapa P; Laco J; Pecen L; Belicova L; Praznovec I; Halaska MJ; Brtnicky T; Salkova E; Rob L; Kodet R; Goc J; Sautes-Fridman C; Fridman WH; Ryska A; Galluzzi L; Spisek R; Fucikova J
J Immunother Cancer; 2018 Dec; 6(1):139. PubMed ID: 30526667
[TBL] [Abstract][Full Text] [Related]
26. Intrauterine device use and risk of ovarian cancer: Results from the New England Case-Control study and Nurses' Health Studies.
Yang J; Sasamoto N; Babic A; Vitonis AF; Townsend MK; Titus L; Cramer DW; Tworoger SS; Terry KL
Int J Cancer; 2021 Jul; 149(1):75-83. PubMed ID: 33634849
[TBL] [Abstract][Full Text] [Related]
27. The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
Hemmingsen CH; Kjaer SK; Bennetsen AKK; Dehlendorff C; Baandrup L
Gynecol Oncol; 2021 Aug; 162(2):469-474. PubMed ID: 34016454
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
29. Impact of Activation of
Sznurkowski JJ; Żawrocki A; Krawczyńska N; Bieńkowski M; Wasąg B; Biernat W
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630004
[No Abstract] [Full Text] [Related]
30. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract][Full Text] [Related]
31. Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin.
Kotsopoulos J; Terry KL; Poole EM; Rosner B; Murphy MA; Hecht JL; Crum CP; Missmer SA; Cramer DW; Tworoger SS
Int J Cancer; 2013 Aug; 133(3):730-9. PubMed ID: 23364849
[TBL] [Abstract][Full Text] [Related]
32. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
34. [Clinical significance of tumor infiltrating lymphocytes in high-grade serous ovarian carcinoma].
Huang XM; Zhang Y; Xu L; Wang M; Wang W
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):610-614. PubMed ID: 31422591
[No Abstract] [Full Text] [Related]
35. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
36. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract][Full Text] [Related]
37. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
Clarke B; Tinker AV; Lee CH; Subramanian S; van de Rijn M; Turbin D; Kalloger S; Han G; Ceballos K; Cadungog MG; Huntsman DG; Coukos G; Gilks CB
Mod Pathol; 2009 Mar; 22(3):393-402. PubMed ID: 19060844
[TBL] [Abstract][Full Text] [Related]
38. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
Corvigno S; Burks JK; Hu W; Zhong Y; Jennings NB; Fleming ND; Westin SN; Fellman B; Liu J; Sood AK
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3545-3555. PubMed ID: 34476576
[TBL] [Abstract][Full Text] [Related]
39. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
40. Anti-Inflammatory Drug Use and Ovarian Cancer Risk by COX1/COX2 Expression and Infiltration of Tumor-Associated Macrophages.
Barnard ME; Hecht JL; Rice MS; Gupta M; Harris HR; Eliassen AH; Rosner BA; Terry KL; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2018 Dec; 27(12):1509-1517. PubMed ID: 30377203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]